The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission
Lilly has long voiced concerns over mass-compounded knockoffs of its tirzepatide medicines, Mounjaro and Zepbound
The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing
One task, one interaction, one pair, experts advocate
The endorsement follows overwhelming support for the share swap preceding the merger,
The conflict is also triggering a widening public health emergency
Subscribe To Our Newsletter & Stay Updated
